Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors
Authors:
- David M. AndrewsDADavid M. Andrews
- Elaine S.E. StokesESElaine S.E. Stokes
- Greg R. CarrGCGreg R. Carr
- Zbigniew S. MatusiakZMZbigniew S. Matusiak
- Craig A. RobertsCRCraig A. Roberts
- Michael J. WaringMWMichael J. Waring
- Madeleine C. BradyMBMadeleine C. Brady
- Christine M. ChrestaCCChristine M. Chresta
- Simon J. EastSESimon J. East
- 1 April 2008
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (8) , 2580-2584
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid MalignanciesClinical Cancer Research, 2007
- Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2007
- Chapter 21 Recent Advances in the Medicinal Chemistry of Histone Deacetylase Inhibitors2007
- VorinostatNature Reviews Drug Discovery, 2007
- Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic MalignanciesJournal of Clinical Oncology, 2006
- Valproic Acid Alters Chromatin Structure by Regulation of Chromatin Modulation ProteinsCancer Research, 2005
- Histone-Deacetylase Inhibitors for the Treatment of CancerCell Cycle, 2004
- Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide DerivativesJournal of Medicinal Chemistry, 1999
- Sinful repressionNature, 1997
- Chromatin structure and the regulation of gene expression: remodeling at the MMTV promoterJournal of Molecular Medicine, 1996